(8S,10S)-8-乙酰基-7,8,9,10-四氢-6,8,11-三羟基-1-甲氧基-10-[[2,3,6-三脱氧-3-[[[[4-(BETA-D-吡喃半乳糖基氧基)-3-硝基苯基]甲氧基]羰基]氨基]-ALPHA-L-来苏-己糖吡喃糖苷]氧基]-5,12-并四苯醌

Daun02 is a prodrug, which is converted by β-galactosidase to Daunorubicin, which has been shown to reduce calcium ion (Ca ²⁺ )-dependent action potentials in neuroblastoma cells. Daunorubicin is a topoisomerase inhibitor. Daun02 is a good substrate for β-galactosidase (β-gal). The concentration of Daun02 producing 50% (EC ₅₀ ) decrease in cell viability is 0.5 μM, 1.5 μM, and 3.5 μM for T47-D, Panc02, and MCF-7, respectively.

Daun02 is a good substrate for β-gal with K _m and V _max values of 0.37 mM and 8.6 μmol/min/mg protein. At a concentration of 10 ^-5 M, Daun02 is 79% bound to plasma protein compares to 94% for Daunomycin.